News Archive

2020

August

Media Release / Aug 20, 2020

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Read More
Media Release / Aug 13, 2020

Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications

Read More
Media Release / Aug 05, 2020

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Read More

June

Media Release / Jun 24, 2020

Novartis announces FDA filing acceptance of Entresto® (sacubitril/valsartan) for patients with heart failure with preserved ejection fraction (HFpEF)

Read More
Media Release / Jun 16, 2020

Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

Read More
Media Release / Jun 16, 2020

Novartis ILARIS® (canakinumab) receives FDA approval for new indication to treat Adult-Onset Still’s Disease (AOSD)

Read More
Media Release / Jun 15, 2020

Novartis manufactures and donates 27,000 units of hand sanitizer to New York State

Read More
Media Release / Jun 11, 2020

U.S. FDA approves updated Novartis BEOVU® label, to include additional safety information

Read More

May

Media Release / May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Read More

Related Links